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Objective: To determine if pseudophakia affects selective laser trabeculoplasty (SLT) 
  intraocular pressure (IOP) lowering effect.
Methods: A retrospective chart review was performed on 94 eyes of 75 consecutive patients who 
underwent SLT as primary treatment for ocular hypertension and primary open-angle glaucoma 
between 2002 and 2005 and completed at least 30 months follow up. Patients were excluded if 
they required additional glaucoma medications, laser, or ocular surgery during the follow-up 
period. Patients were categorized as phakics or pseudophakics. Independent-samples t-test was 
performed to compare the mean percentage of IOP reduction at 3, 6, 12, 18, and 30 months after 
SLT between the phakic and pseudophakic groups.
Results: Seventy-six phakic and 18 pseudophakic eyes were included. IOP reduction in   phakic 
group was 27.4% (2 week), 29.8% (3 months), 27.7% (9 months), 27.4% at (12 months) and 
27.3% at (30 months). In pseudophakic patients, the mean IOP reduction was 19.8% (2 weeks), 
26.5% (3 months), 23.2% (9 months), 22.5% (12 months), and 25.9% (30 months). An 
independent-sample t-test compared the percentage of IOP reduction between the phakic and 
pseudophakic groups and revealed higher percentage of IOP reduction in the phakic group at 
2 weeks by 7.6% (P = 0.01). P value for difference was 0.34 (3 months), 0.25 (6 months), 0.18 
(9 months), 0.12 (12 months), 0.36 (18 months), and 0.7 (30 months) after SLT.
Conclusions: SLT response was delayed in pseudophakic compared to phakic patients, while 
the long-term effectiveness of SLT is the same in both groups.
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Introduction
Medical treatment, laser trabeculoplasty, and surgery can be used to control intraocular 
pressure (IOP) in patients with ocular hypertension (OHT) and primary open-angle 
glaucoma (POAG).
Latina et al demonstrated that a 532-nm Q-switched Nd:YAG laser with nanosecond 
pulse duration is capable of selectively targeting pigmented trabecular meshwork cells 
without collateral thermal damage to the adjacent nonpigmented trabecular meshwork 
cells and underlying trabecular beams.1–3
SLT can also be used to lower the IOP in high-risk OHT patients and patients with 
pseudoexfoliation glaucoma.4,5
Clear corneal phacoemulsification (CCP) is associated with a statistically 
  significant and sustained reduction in IOP in normal subjects6–9 as well as in patients 
with POAG.10–13 The exact mechanism by which cataract extraction lowers IOP is 
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It is plausible that CCP and SLT may share a common 
pathway involving inflammation, prostaglandin release, and 
interleukin-1α release. This lead us to the hypothesis that 
the IOP response to SLT may be different in pseudophakic 
eyes compared to phakic eyes due to partial or completely 
activation of pathways common to SLT response and CCP-
mediated IOP-lowering effect in the former group.
A prior study by Werner et al compared outcome of SLT 
as a secondary treatment for glaucoma in pseudophakic 
versus phakic patients.14 We know of no prior study in the 
literature that evaluates the effect of primary SLT on IOP in 
pseudophakic eyes.
The purpose of this study is to determine if pseudophakia 
affects the IOP-lowering effect of primary SLT in patients 
with OHT and POAG.
Methods
This is a retrospective study, which included all patients who 
had SLT performed by Dr Latina between February 2002 
and December 2005. The aforementioned data were gathered 
from the postoperative visits at week 2 and 3, 6, 9, 12, 24, 
and 30 months. Inclusion criteria included having SLT done 
as a primary therapy, having either OHT or POAG, and the 
recording of all data at all time points. The patients included 
in the study were either first diagnosed with high-risk OHT 
or mild-to-moderate POAG. Patients were excluded if they 
received an OHT medication or had an intraocular surgery 
performed during the 30 months following SLT. Patients 
with history of recent cataract surgery (within 6 months), 
complicated cataract surgery or prior laser trabeculoplasty 
(LTP) were excluded.
Patients were categorized as phakics if the crystalline 
lens was present, or pseudophakics if a posterior chamber 
IOL (PCIOL) was present. All pseudophakic patients had 
their cataracts removed via uneventful phacoemulsifica-
tion with insertion of a foldable hydrophobic PCIOL in the 
capsular bag by the same surgeon (MAL) under retrobulbar 
anesthesia. All pseudophakic patients were treated postop-
eratively with a topical prednisolone acetate 1% four times 
daily with gradual taper for 8 weeks, topical antibiotics and 
topical nonsteroidal anti-inflammatory eyedrops three times 
daily for 3 weeks.
The laser procedure was performed in a standard fash-
ion in all cases. An initial power setting between 0.6 mJ 
and 0.9 mJ was selected. The procedure was then com-
pleted for 180 degrees. The endpoint was to visualize fine 
bubble(s) at the laser treated area, and the intended number 
of spots was between 55 and 70. Patients received   topical 
apraclonidine 0.5%, 15 minutes before the procedure. 
Patients were treated with ketorlac tromethamine 0.4% two 
times daily for 2 days following the procedure.
The statistical analysis was performed using the Statistical 
Program for the Social Sciences (Version 16.0; SPSS Inc, 
Chicago, IL).
Independent-samples t-test was performed to compare 
the mean percentage of IOP reduction at 3, 6, 12, 18 and 
30 months after SLT between the phakic and pseudophakic 
groups. Independent-samples t-test was performed to com-
pare the mean baseline IOP at the time of doing SLT between 
the phakic and pseudophakic groups. An Institutional Review 
Board was not required as the authors studied retrospectively 
existing data recorded by the authors in such a manner that 
subjects cannot be identified directly or through identifiers 
linked to the subjects.
Results
The age and sex of the 75 patients were consistent with a 
glaucomatous population (Table 1). POAG comprised the 
primary indication (60.6%) for the procedure, while ocular 
hypertension represented 39.4% of the patients undergoing 
SLT. Seventy-six of included eyes were phakic (80.9%) and 
18 were pseudophakic (19.1%).
The  baseline  IOP  for  the  phakic  group  was 
24.1 ± 3.3 mmHg (range, 17–31 mmHg), while the base-
line IOP for the pseudophakic group was 22.6 ± 3.8 mmHg 
(range, 14–32 mmHg). Baseline IOP was not significantly 
different between the 2 groups (P = 0.13).
Mean IOP reduction in the phakic group was 27.4% ± 11.5% 
at 2 weeks, 29.8% ± 13.1% at 3 months, 28% ± 13.4% at 
6 months, 27.7% ± 13.1% at 9 months, 27.4% ± 13.5% at 
12 months, and 27.3% ± 12.9% at 30 months. Mean IOP 
reduction in the   pseudophakic group was 19.8% ± 10.3% 
at 2 weeks, 26.5% ± 12.6% at 3 months, 24.3% ± 11.8% at 
Table 1 Baseline characteristics of sample (n = 94 eyes of 75 
patients)
Characteristic
Age (SD) 66.63 (10.36) years
Sex 63.8% women
Baseline iOP (SD) (mmhg) 23.84 (3.4)
Procedure parameters
Average energy per shot (W) (SD) 0.90 (0.17)
Average number of shots (SD) 76.82 (34.2)
Average total energy (W) (SD) 68.19 (41.44)
Glaucoma diagnosis in eyes (no. of patients)
Primary open-angle glaucoma 57 (45)
Ocular hypertension 37 (29)
Abbreviations: iOP, intraocular pressure; SD, standard deviation.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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6 months, 23.2% ± 12.3% at 9 months, 22.5% ± 10.8% at 
12 months, and 25.9% ± 4.2% at 30 months (Table 2).
An independent-samples t-test was performed to compare 
the mean percentages of IOP reduction between the phakic 
and pseudophakic groups. The test revealed higher mean 
percentage of IOP reduction in the phakic group at 2 weeks 
(7.6%; P = 0.01). The differences in mean percentage of IOP 
reduction between the phakic and pseudophakic groups were 
not statistically significant at 3–30 months post-SLT. The 
P value for difference was 0.34 (3 months), 0.25 (6 months), 
0.18 (9 months), 0.12 (12 months), 0.36 (18 months), and 
0.7 (30 months) after SLT (see Table 2).
Discussion
Review of literature showed that SLT is a viable option as a 
primary or adjuvant treatment for patients with OHT, POAG, 
and pseudoexfoliation glaucoma.5,15–18 SLT is not only as 
effective as medical treatment, but also a more economic 
treatment option.19 Johnson et al showed that the 2-week 
visit post-SLT predicted the 4-week and 3-month visits in 
the same eye if the 2-week visit demonstrated a decrease in 
IOP.20 Different studies showed the predictive value of the 
baseline IOP as a predictor of success following SLT.21–22 It 
was shown that SLT not only lowers the IOP in the treated 
eye, but also has a short-term IOP-lowering effect in the 
untreated eye.23
Clear corneal phacoemulsification (CCP) is associated 
with a statistically significant and sustained reduction in 
IOP, both in normal subjects6–9 as well as in patients with 
POAG.10–13 The exact mechanism by which cataract extrac-
tion lowers IOP is not yet fully understood.
Many hypotheses have been postulated in the literature,12 
namely 1) hyposecretion of aqueous humor secondary to cili-
ary body inflammation, 2) increased outflow of aqueous humor 
via increased endogenous prostaglandins secretion, produc-
tion of interleukin-1α by trabecular meshwork, and finally 3) 
mechanical irrigation during   phacoemulsification flushes 
the trabeculum, thereby decreasing outflow resistance,12 
or by the widening effect of lens extraction on the anterior 
chamber angle.
It is plausible that CCP and SLT may share a common 
pathway involving inflammation, prostaglandin release and 
or interleukin-1α release.
Our study shows that the percentage of IOP reduction 
following SLT in pseudophakic eyes is significantly less 
than that of SLT in phakic eyes at 2 weeks. However, from 
the 3-month visit until the end of the follow-up period 
(30 months), the mean percentages of IOP reduction fol-
lowing SLT was slightly lower in the pseudophakic group, 
but was not statically significant (Table 2). This may be at 
least partially explained by the possibility that SLT and CCP 
share common pathways possibly involving inflammatory 
mediators.
Thus, in pseudophakic eyes, the IOP-lowering effect 
of SLT may not be completely achieved at 2 weeks post-
SLT. It may be too early to judge SLT success at this point. 
Instead, the 3-month IOP should be used. Starting glaucoma 
medications, repeating SLT, or doing a glaucoma surgery in 
these patients based on their 2-week visit IOP may not be 
appropriate.
The results of this study concurs with a prior study by 
Werner et al showing equivalent effect outcome of SLT as a 
secondary treatment of glaucoma in phakic and pseudophakic 
patients.14 Martow et al showed that pseudophakia doesn’t 
predict SLT success or failure in OHT and POAG patients 
undergoing SLT as an adjunctive treatment.24 Our study 
demonstrates no negative effect of prior cataract surgery 
with PCIOL implantation on the outcome of primary SLT 
in patients with OHT and POAG.
Further studies are required to explore the relationship 
between the IOP-lowering effect of cataract extraction and 
that of SLT.
Table 2 Percentage of iOP reduction following SLT
Phakic group (n = 18) Pseudophakic group (n = 76) t-test  
P-value Mean SD Mean SD
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At 2 weeks 27.4 11.5 19.8 10.3 0.01*
At 3 months 29.8 13.1 26.5 12.6 0.34
At 6 months 28.0 13.4 24.3 11.8 0.25
At 9 months 27.7 13.1 23.2 12.3 0.18
At 12 months 27.4 13.5 22.5 10.8 0.12
At 18 months 26.2 13.3 22.8 13.8 0.36
At 30 months 27.3 12.9 25.9 14.2 0.7
Note: *Statistically significant difference at P , 0.05.
Abbreviations: iOP, intraocular pressure; SD, standard deviation; SLT, selective laser trabeculoplasty.Clinical Ophthalmology
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Conclusion
Phakic patients with POAG and OHT showed a signifi-
cantly higher percentage of IOP reduction at 2 weeks after 
SLT compared to pseudophakic patients. No statistically 
significant difference in percentage of IOP reduction was 
found between the 2 groups at 3–30 months after SLT. These 
findings   suggest that, SLT response seems to be delayed 
in pseudophakic compared to phakic patients, while the 
long-term effectiveness of SLT is the same for phakic and 
pseudophakic patients. More time should be allowed to judge 
the success of SLT in pseudophakic patients.
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